Table 4. Table of results.
Test-treat strategy | Cost | Women successfully treated | QALYs | ICER per woman successfully treated | ICER per QALY |
---|---|---|---|---|---|
First analysis | |||||
Urodynamics | £4,524 | 0.615 | 3.669 | ||
Clinical history | £5,801 | 0.618 | 3.691 | £491,100 | £60,200 |
Bladder ultrasonography | £5,947 | 0.615 | 3.621 | Dominated | Dominated |
Second analysis | |||||
Urodynamics—All women | £4,524 | 0.615 | 3.669 | ||
Urodynamics—Conditional on clinical history of mixed incontinence | £5,126 | 0.646 | 3.717 | £19,500 | £12,700 |
Urodynamics—Conditional on clinical history of overactive bladder | £5,198 | 0.587 | 3.643 | Dominated | Dominated |
Bladder ultrasonography—Conditional on clinical history of mixed incontinence | £5,768 | 0.654 | 3.689 | £78,600 | Dominated |
Clinical history—All women | £5,801 | 0.618 | 3.691 | Dominated | Dominated |
Bladder ultrasonography—All women | £5,947 | 0.615 | 3.621 | Dominated | Dominated |
Bladder ultrasonography—Conditional on clinical history of overactive bladder | £5,965 | 0.596 | 3.636 | Dominated | Dominated |
QALY, quality-adjusted life-year; ICER, incremental cost-effectiveness ratio.